SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Morgan Stanley Maintains Eli Lilly at Overweight, Raises Target to $1,596

Morgan Stanley maintained its Overweight rating on Eli Lilly and raised its price target to $1,596 from $1,430.

LLY
SquawkNews Desk 1 updates Updated Oct 30, 2026, 06:12 PM UTC

Story updates

06:12:10 PM UTC
SquawkNews
Eli Lilly Is Maintained at Overweight by Morgan Stanley

Related stories

SpaceX President Shotwell Says 2 Million Shares to Go to Trump Accounts SpaceX President Gwynne Shotwell says 2 million shares will be gifted to children's Trump Accounts. M impact | EQUITY | Oct 30, 2026, 09:38 PM UTC US Elections, Earnings and Jobs Data Loom for AI-Wary Stocks A preview flags midterm elections, earnings and jobs data as coming events for an AI-wary stock market. M impact | EQUITY | Oct 30, 2026, 09:32 PM UTC Digital Realty Registers Resale of Shares Issued in Teraco Stake Acquisition Digital Realty registered the resale of shares issued in its acquisition of a stake in Teraco. M impact | EQUITY | Oct 30, 2026, 09:29 PM UTC S&P Global Revises Meta Outlook to Negative on Cash Flow Concerns M impact | EQUITY | Oct 30, 2026, 09:22 PM UTC Bank of America Reports Third-Quarter Revenue of $30B, Net Income of $6.5B Bank of America reported third-quarter 2026 revenue of $30B, up 3.2% year over year. Net income applicable to common shareholders fell 17.2% to $6.5B, and diluted EPS declined 12.5 H impact | EQUITY | Oct 30, 2026, 09:11 PM UTC VantageScore CEO Silvio Tavares Resigns After Five Years VantageScore said Silvio Tavares is stepping down as president and CEO after leading the company for five years. Anthony Hutchinson was named interim president and CEO. M impact | EQUITY | Oct 30, 2026, 09:07 PM UTC